Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 98.00p 96.75p 99.00p - - - 0 06:33:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -6.3 -4.5 - 129.87

Immupharma Share Discussion Threads

Showing 10801 to 10823 of 10825 messages
Chat Pages: 433  432  431  430  429  428  427  426  425  424  423  422  Older
DateSubjectAuthorDiscuss
20/11/2017
07:49
Not long to go now. Phase 3 finishes in about eight weeks. This could rocket.
top tips
20/11/2017
07:46
LOL....So the FDA gave Immupharma a SPA, Gold Standard, and fast track approval on poor Phase 2 results.....I don't think so.
flavio_monteiro
20/11/2017
07:46
Alphapig for selfish reasons i hope it dose go sub 90 so i can add a few good luck all
scoredagain
20/11/2017
07:23
Surprised by Wigwammer claim as Cephelon started a 2nd phase 2b (not phase 3) which was stopped when IMM took back ownership when Teva bought Cephelon.
waterloo01
20/11/2017
03:27
The only mention of a Phase III in that link wigwammer was for Belimumab which I believe is Benlysta?
spawny100
20/11/2017
01:44
Alpha: they are trying hard to :-)
l0ngterm
20/11/2017
01:42
Alpha: they are trying hard lol
l0ngterm
20/11/2017
01:38
If they can get this down sub 90, count me in for a fair few. Keep it up mamma.
alphapig
20/11/2017
01:28
Wigwammer: the only mention of phase III in that link is for a different drug.Have you got your wires crossed?
l0ngterm
20/11/2017
01:18
Spawny: please read my earlier posts.Wigwammer: please back up your statement, thanks. As I can't see any trial on clinical trials .gov etc with published phase III results?
l0ngterm
20/11/2017
01:03
Wigwammer: I didn't state those were the results, for a b failed phase III. I said they were from the excipient feedback. I cannot see any results from a phase III trial, or evidence ofphase III results.Can you please backup your statement by referencing the results you are referring to.
l0ngterm
20/11/2017
00:04
FYI Nov 2017 article summarising Lupus treatments in late stage development: htTps://www.ptcommunity.com/journal/article/full/2017/6/394/immunotherapies-late-stage-development-patients-severe-sle-andor
spacehorse
19/11/2017
23:20
Spawny - it was a ph3 and it failed.Hottingup - I hope so. Not an unblemished clinical record though, and anyone weighing up the risk and return should bear all the facts in mind.
wigwammer
19/11/2017
23:15
Cephalon used the wrong excipient in their Lupuzor trial, that is well known and understood. It was Cephalon and their choice of excipient that was at fault, not the active drug Lupuzor. Sylvianne Muller actually told Cephalon they were using the wrong excipient but Cephalon chose to ignore her advice. When the correct excipient was subsequently used by IMM after they regained control of Lupuzor (as Cephalon should have used) Lupuzor produced the best Phase 2b results for treating lupus ever recorded for any lupus drug. IMM's current Phase 3 Lupuzor trial is using the same excipient as they used in their highly successful Phase 2b trial. This is the data the regulators will be considering and is all that matters.
hottingup
19/11/2017
23:12
5775 Am I missing something wigwammer? No reference to a phase III trial in that link.
spawny100
19/11/2017
23:09
Longterm - just reading your post again... not sure why you state the results were never released but then include the results in your post.
wigwammer
19/11/2017
23:06
hmm scoredagin( not a typo);)07/10/217 joined? ha
mitch101
19/11/2017
22:51
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232263/#!po=26.5625Table 1.I own IMM shares, I hope that it does turn out the excipient is the issue. The risk/reward appears attractive. But having failed a ph3, lupuzor evidently does not have an uncompromised body of clinical evidence as was previously suggested.
wigwammer
19/11/2017
22:32
scoredagain - are you an investor in IMM? If so what do you think are the odds of Lupuzor passing phase III? Appreciate views from a well informed person on IMM and its flagship drug. Thanks.
divinessence
19/11/2017
22:02
wIGWAMMER please dig deep for this news when u said it failed . Im well informed on imm and to my knowledge it has never failed . I will email lisa tmw as per normal she normally comes back in a day or so . I would be so SURPRISED IF IT HAS
scoredagain
19/11/2017
21:27
I believe that's the results I posted above then, demonstrating the impact trelahose had.Oddly the challenges the company and scientist have encountered. And the subsequent investigations into the excipients, method of action and the CNRS reconfirming lupuzor.Have reinforced my confidence, as lupuzor has had more eyes on it than just a pass fail trial. The excipients work alone has been referenced in several other scientific documents, and has not been rejected in anyway. The work has been referenced as evidence to support further analysis when selecting excipients, and this trials used as an example to support this.Overall we still have risk that lupuzor fails, but all this work bolsters my investment decision.What about you?
l0ngterm
19/11/2017
21:14
Longterm - from memory, it was contained in the initial research relating to the excipient comparison.Would have to do some digging to find the document - unless someone else has it to hand?
wigwammer
19/11/2017
20:56
Wigwammer: in addendum to this please see a post from SK in relation to this matter in 2012.Interesting in the post it states the results were never released. So can you please share where you have found these results, for the failed phase III?1. "ImmuPharma was not very adequately apprised of the development progress by Cephalon for Lupuzor. Although a joint steering committee was envisaged, no meetings took place". 2. "As soon as it was apparent that Cephalon would be acquired, ImmuPharma determined that it would be in its best interests to recover the rights to Lupuzor and re-license them to a third party. This was in part a reflection of concerns with Cephalon's development of Lupuzor and the unknown commitment of the acquiring party to the product."3. "In June 2010, Cephalon initiated a 220-patient, 24-week Phase IIb study of Lupuzor, delaying the start of a hitherto expected Phase III study. ImmuPharma was also concerned by this as it transpired that the study was examining a new formulation stabilised with trehalose (referred to as forigerimod) rather than the previously-used mannitol in an attempt to provide a longer shelf life."4. "ImmuPharma had particular concerns about the use of trehalose as its scientific collaborators at the CNRS had generated data suggesting that this could reduce Lupuzor's activity. The CNRS had warned Cephalon that this excipient could compromise efficacy. Furthermore, ImmuPharma believes it is not commercially necessary to achieve a longer shelf life than was available with mannitol."5. "In August 2011 Cephalon closed recruitment into the Phase IIb study at 137 patients, of the planned 220 patients, and re-designated it to be a Phase III trial so as to provide safety data that could be used in support of a regulatory filing. Unconfirmed and unsubstantiated reports at the time suggested an 'inconclusive' interim analysis of the Phase IIb study, despite the fact the data was blinded. Cephalon did not announce any data and final results are unlikely to be released."6. "ImmuPharma's licensing deal with Cephalon turned out to be well structured, and combined with certain other factors (notably it was governed by Swiss law) provided a strong basis for enforcing the return of rights. This was triggered by the change of control and breach of non-compete provisions (Teva is developing laquinimod, initially as a potential MS therapy, but Phase II studies in lupus nephritis are also ongoing)."7. "ImmuPharma was thus able to enforce its contractual rights and recover the commercial rights to Lupuzor and without any ongoing financial obligation. Teva has returned all clinical data, regulatory filings and correspondence with regulators. ImmuPharma has since also been able to take over contracts with third-party suppliers for physical product etc."
l0ngterm
Chat Pages: 433  432  431  430  429  428  427  426  425  424  423  422  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171120 07:55:50